Literature DB >> 21134472

Prognostic prediction of therapeutic response in depression using high-field MR imaging.

Qiyong Gong1, Qizhu Wu, Cristina Scarpazza, Su Lui, Zhiyun Jia, Andre Marquand, Xiaoqi Huang, Philip McGuire, Andrea Mechelli.   

Abstract

Despite significant advances in the treatment of major depression, there is a high degree of variability in how patients respond to treatment. Approximately 70% of patients show some improvement following standard antidepressant treatment and are classified as having non-refractory depressive disorder (NDD), while the remaining 30% of patients do not respond to treatment and are classified as having refractory depressive disorder (RDD). At present, there are no objective, neurological markers which can be used to identify individuals with depression and predict clinical outcome. We therefore examined the diagnostic and prognostic potential of pre-treatment structural neuroanatomy using support vector machine (SVM). Sixty-one drug-naïve adults suffering from depression and 42 healthy volunteers were scanned using structural magnetic resonance imaging (sMRI). Patients then received standard antidepressant medication (either tricyclic, typical serotonin-norepinephrine reuptake inhibitor or typical selective serotonin reuptake inhibitor). Based on clinical outcome, we selected two groups of RDD (n=23) and NDD (n=23) patients matched for age, sex and pre-treatment severity of depression. Diagnostic accuracy of gray matter was 67.39% for RDD (p=0.01) and 76.09% for NDD (p<0.001), while diagnostic accuracy of white matter was 58.70% for RDD (p=0.13) and 84.65% for NDD (p<0.001). SVM applied to gray matter correctly distinguished between RDD and NDD patients with an accuracy of 69.57% (p=0.006); in contrast, SVM applied to white matter predicted clinical outcome with an accuracy of 65.22% (p=0.02). These results indicate that both gray and white matter have diagnostic and prognostic potential in major depression and may provide an initial step towards the use of biological markers to inform clinical treatment. Future studies will benefit from the integration of structural neuroimaging with other imaging modalities as well as genetic, clinical and cognitive information.
Copyright © 2010. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21134472     DOI: 10.1016/j.neuroimage.2010.11.079

Source DB:  PubMed          Journal:  Neuroimage        ISSN: 1053-8119            Impact factor:   6.556


  86 in total

1.  Disease prediction in the at-risk mental state for psychosis using neuroanatomical biomarkers: results from the FePsy study.

Authors:  Nikolaos Koutsouleris; Stefan Borgwardt; Eva M Meisenzahl; Ronald Bottlender; Hans-Jürgen Möller; Anita Riecher-Rössler
Journal:  Schizophr Bull       Date:  2011-11-10       Impact factor: 9.306

2.  Control-group feature normalization for multivariate pattern analysis of structural MRI data using the support vector machine.

Authors:  Kristin A Linn; Bilwaj Gaonkar; Theodore D Satterthwaite; Jimit Doshi; Christos Davatzikos; Russell T Shinohara
Journal:  Neuroimage       Date:  2016-02-23       Impact factor: 6.556

3.  The 5-HTTLPR and BDNF polymorphisms moderate the association between uncinate fasciculus connectivity and antidepressants treatment response in major depression.

Authors:  Erica L Tatham; Geoff B C Hall; Darren Clark; Jane Foster; Rajamannar Ramasubbu
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-06-08       Impact factor: 5.270

Review 4.  The role of machine learning in neuroimaging for drug discovery and development.

Authors:  Orla M Doyle; Mitul A Mehta; Michael J Brammer
Journal:  Psychopharmacology (Berl)       Date:  2015-05-28       Impact factor: 4.530

Review 5.  [Neuroimaging in psychiatry: multivariate analysis techniques for diagnosis and prognosis].

Authors:  J Kambeitz; N Koutsouleris
Journal:  Nervenarzt       Date:  2014-06       Impact factor: 1.214

Review 6.  Progress in Elucidating Biomarkers of Antidepressant Pharmacological Treatment Response: A Systematic Review and Meta-analysis of the Last 15 Years.

Authors:  G Voegeli; M L Cléry-Melin; N Ramoz; P Gorwood
Journal:  Drugs       Date:  2017-12       Impact factor: 9.546

7.  The Canadian Biomarker Integration Network in Depression (CAN-BIND): magnetic resonance imaging protocols

Authors:  Glenda M. MacQueen; Stefanie Hassel; Stephen R. Arnott; Addington Jean; Christopher R. Bowie; Signe L. Bray; Andrew D. Davis; Jonathan Downar; Jane A. Foster; Benicio N. Frey; Benjamin I. Goldstein; Geoffrey B. Hall; Kate L. Harkness; Jacqueline Harris; Raymond W. Lam; Catherine Lebel; Roumen Milev; Daniel J. Müller; Sagar V. Parikh; Sakina Rizvi; Susan Rotzinger; Gulshan B. Sharma; Claudio N. Soares; Gustavo Turecki; Fidel Vila-Rodriguez; Joanna Yu; Mojdeh Zamyadi; Stephen C. Strother; Sidney H. Kennedy
Journal:  J Psychiatry Neurosci       Date:  2019-07-01       Impact factor: 6.186

Review 8.  Annual research review: Current limitations and future directions in MRI studies of child- and adult-onset developmental psychopathologies.

Authors:  Guillermo Horga; Tejal Kaur; Bradley S Peterson
Journal:  J Child Psychol Psychiatry       Date:  2014-01-20       Impact factor: 8.982

9.  A functional MRI marker may predict the outcome of electroconvulsive therapy in severe and treatment-resistant depression.

Authors:  J A van Waarde; H S Scholte; L J B van Oudheusden; B Verwey; D Denys; G A van Wingen
Journal:  Mol Psychiatry       Date:  2014-08-05       Impact factor: 15.992

Review 10.  Towards automated detection of depression from brain structural magnetic resonance images.

Authors:  Kuryati Kipli; Abbas Z Kouzani; Lana J Williams
Journal:  Neuroradiology       Date:  2013-01-22       Impact factor: 2.804

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.